NCT01782300View on ClinicalTrials.gov

Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

September 30, 2016

Conditions
Dengue
Interventions
BIOLOGICAL

TV003 Vaccine

TV003 will contain an admixture of the following monovalent dengue vaccines: 10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.

BIOLOGICAL

Placebo Vaccine

Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.

Trial Locations (2)

21205

Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore

05405

University of Vermont Vaccine Testing Center, Burlington

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01782300 - Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart | Biotech Hunter | Biotech Hunter